Surface Oncology (Nasdaq:SURF) - Cotización, noticias y análisis

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Resumen de acción SURF

Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. Saber más

Análisis fundamental de SURF
Puntuación del snowflake
Valoración	2/6
Crecimiento futuro	0/6
Rendimiento pasado	0/6
Salud financiera	4/6
Dividendos	0/6

Análisis de riesgos

Tiene menos de 1 año de cash runway

Tiene unos ingresos inferiores a 1 millón de dólares ($0)

Actualmente no es rentable y no se prevé que lo sea en los próximos 3 años

Los accionistas han sido diluidos en el último año

+ 1 riesgos adicionales

Competidores de Surface Oncology, Inc.

Homology Medicines

NasdaqGS:FIXX

US$54.3m

MediciNova

NasdaqGM:MNOV

US$100.5m

SAB Biotherapeutics

NasdaqCM:SABS

US$28.0m

CollPlant Biotechnologies

NasdaqGM:CLGN

US$48.8m

Historial de precios y rendimiento

Resumen de todos los máximos históricos, cambios y caídas de precios de Surface Oncology
Precios históricos de las acciones
Precio actual de la acción	US$1.07
Máximo en las últimas 52 semanas	US$1.43
Mínimo de 52 semanas	US$0.56
Beta	1.75
1Cambio en 1 mes	11.47%
Variación en 3 meses	38.96%
Cambio de 1 año	-21.90%
3Variación en 3 años	-83.79%
Variación en 5 años	-89.91%
Variación desde la OPV	-91.97%

Noticias y actualizaciones recientes

Recent updates

Forecast: Analysts Think Surface Oncology, Inc.'s (NASDAQ:SURF) Business Prospects Have Improved Drastically

Nov 07

Analysts Just Made A Major Revision To Their Surface Oncology, Inc. (NASDAQ:SURF) Revenue Forecasts

Aug 08

Surface Oncology GAAP EPS of -$0.46 misses by $0.01

Aug 03

Surface Oncology: Neither Novartis, Nor GSK Or ARKG Is Able To Stop The Decline

May 25

News Flash: Analysts Just Made A Dazzling Upgrade To Their Surface Oncology, Inc. (NASDAQ:SURF) Forecasts

May 11

Here's What Surface Oncology, Inc.'s (NASDAQ:SURF) Shareholder Ownership Structure Looks Like

Mar 15

Does Surface Oncology (NASDAQ:SURF) Have A Healthy Balance Sheet?

Feb 16

Surface Oncology: Early Stage Cancer-Specific Company With Novel Assets

Dec 09

What Kind Of Shareholders Hold The Majority In Surface Oncology, Inc.'s (NASDAQ:SURF) Shares?

Dec 08

Surface Oncology shares rise 13% on Fast Track tag for SRF388

Nov 11

Rentabilidad de los accionistas

	SURF	US Biotechs	Mercado US
7D	-0.9%	4.0%	2.0%
1Y	-21.9%	18.0%	32.4%

Rentabilidad vs. Industria: Los resultados de SURF fueron inferiores a los de la industria US Biotechs, que obtuvo un rendimiento del 18% el año pasado.

Rentabilidad vs. Mercado: SURF obtuvo unos resultados inferiores a los del mercado US, que fueron del 32.4% el año pasado.

Volatilidad de los precios

Is SURF's price volatile compared to industry and market?
SURF volatility
SURF Average Weekly Movement	8.3%
Biotechs Industry Average Movement	9.8%
Market Average Movement	6.3%
10% most volatile stocks in US Market	15.9%
10% least volatile stocks in US Market	3.1%

Precio estable de las acciones: El precio de las acciones de SURF ha sido volátil en los últimos 3 meses.

Volatilidad a lo largo del tiempo: La volatilidad semanal de SURF (8%) se ha mantenido estable durante el año pasado.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
2014	35	Rob Ross	www.surfaceoncology.com

Resumen de fundamentos de Surface Oncology, Inc.

¿Cómo se comparan los beneficios e ingresos de Surface Oncology con su capitalización de mercado?
Estadísticas fundamentales de SURF
Capitalización bursátil	US$65.08m
Beneficios(TTM)	-US$92.50m
Ingresos (TTM)	n/a

0.0x

Ratio precio-ventas (PS)

-0.7x

Ratio precio-beneficio (PE)

¿Está SURF sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de SURF
Ingresos	US$0
Coste de los ingresos	US$67.00m
Beneficio bruto	-US$67.00m
Otros gastos	US$25.50m
Beneficios	-US$92.50m

Últimos beneficios comunicados

Jun 30, 2023

Próxima fecha de beneficios

n/a

Beneficios por acción (BPA)	-1.52
Margen bruto	0.00%
Margen de beneficio neto	0.00%
Ratio deuda/patrimonio	0%

¿Cómo se ha desempeñado SURF a largo plazo?

Ver rendimiento histórico y comparativa

This company has been acquired

Resumen de acción SURF

Análisis de riesgos

Competidores de Surface Oncology, Inc.

NasdaqGS:FIXX

US$54.3m

NasdaqGM:MNOV

US$100.5m

NasdaqCM:SABS

US$28.0m

NasdaqGM:CLGN

US$48.8m

Historial de precios y rendimiento

Noticias y actualizaciones recientes

Coherus BioSciences, Inc. (NasdaqGM:CHRS) completed the acquisition of Surface Oncology, Inc. (NasdaqGM : SURF) from Novartis Institutes for BioMedical Research, Inc., Atlas Venture Fund IX, L.P., managed by Atlas Venture L.P., ARK Investment Management LLC, EcoR1 Capital, LLC and others.

Nasdaq Approves Surface Oncology, Inc.'s Common Stock Transfer the Listing from the Nasdaq Global Market to the Nasdaq Capital Market

Coherus BioSciences, Inc. (NasdaqGM:CHRS) entered into a definitive merger agreement to acquire Surface Oncology, Inc. (NasdaqGM : SURF) for transaction value of $65 million.

Consensus revenue estimates decrease by 17%, EPS upgraded

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Surface Oncology Receives A Deficiency Letter from the Nasdaq Regarding Minimum Bid Price Requirement

Recent updates

Coherus BioSciences, Inc. (NasdaqGM:CHRS) completed the acquisition of Surface Oncology, Inc. (NasdaqGM : SURF) from Novartis Institutes for BioMedical Research, Inc., Atlas Venture Fund IX, L.P., managed by Atlas Venture L.P., ARK Investment Management LLC, EcoR1 Capital, LLC and others.

Nasdaq Approves Surface Oncology, Inc.'s Common Stock Transfer the Listing from the Nasdaq Global Market to the Nasdaq Capital Market

Coherus BioSciences, Inc. (NasdaqGM:CHRS) entered into a definitive merger agreement to acquire Surface Oncology, Inc. (NasdaqGM : SURF) for transaction value of $65 million.

Consensus revenue estimates decrease by 17%, EPS upgraded

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Surface Oncology Receives A Deficiency Letter from the Nasdaq Regarding Minimum Bid Price Requirement

Vaccinex, Inc. Announces First Patient Dosed with Anti-Ccr8 Antibody Licensed to Surface Oncology

Surface Oncology Announces First Patient Dosed in a Phase 1/2 Study Evaluating SRF114, a Potential Best-In-Class Anti-CCR8 Antibody, in Patients with Advanced Solid Tumors

Price target decreased to US$5.25

Consensus forecasts updated

Forecast: Analysts Think Surface Oncology, Inc.'s (NASDAQ:SURF) Business Prospects Have Improved Drastically

Third quarter 2022 earnings released: US$0.39 loss per share (vs US$0.44 loss in 3Q 2021)

Surface Oncology to Present Preclinical Data Highlighting the IL-27 Gene Expression Signature in Treatment-Resistant Cancers at the 10th Annual International Cytokine and Interferon Society Meeting

Analysts Just Made A Major Revision To Their Surface Oncology, Inc. (NASDAQ:SURF) Revenue Forecasts

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Surface Oncology GAAP EPS of -$0.46 misses by $0.01

Surface Oncology Appoints Carsten Brunn to Board of Directors

Surface Oncology, Inc. Announces Publication of New Study Demonstrating the Role of the IL-27 Pathway in Hepatocellular Carcinoma

Surface Oncology, Inc. Presents New SRF388 Clinical Data At 2022 American Society of Clinical Oncology Annual Meeting

Surface Oncology: Neither Novartis, Nor GSK Or ARKG Is Able To Stop The Decline

Consensus revenue estimates increase by 46%

News Flash: Analysts Just Made A Dazzling Upgrade To Their Surface Oncology, Inc. (NASDAQ:SURF) Forecasts

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Surface Oncology, Inc. to Present Clinical Update on SRF388 at American Society of Clinical Oncology Annual Meeting

Price target decreased to US$13.00

Surface Oncology, Inc. Announces Initiation of Phase 2 Studies Evaluating SRF388 in Patients with Hepatocellular Carcinoma and Non-Small-Cell Lung Cancer

Surface Oncology Achieves $30 Million Milestone with First Patient Dosed in GlaxoSmithKline Phase 1 Study

Consensus forecasts updated

Price target decreased to US$14.75

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Surface Oncology Announces Stepping Down of Geoffrey McDonough from the Board of Directors

Surface Oncology Announces Stepping Down of Geoffrey McDonough from the Board of Directors

Does Surface Oncology (NASDAQ:SURF) Have A Healthy Balance Sheet?

Surface Oncology: If Novartis, GlaxoSmithKline And ARK See Promise, So Do I

Surface Oncology to Present New Clinical Data from Ongoing SRF617 Phase 1 Trial at the European Society for Medical Oncology Immuno-Oncology Congress (ESMO-IO) 2021

Surface Oncology Announces FDA Clearance of IND Application for GSK4381562

Investor sentiment deteriorated over the past week

Is Surface Oncology (NASDAQ:SURF) A Risky Investment?

Surface Oncology: Staying The Course

Investor sentiment improved over the past week

Consensus revenue estimates fall to US$21.0m

Investor sentiment deteriorated over the past week

Surface Oncology: A Diverse, But Early Pipeline

Chairman of the Board exercised options and sold US$862k worth of stock

Investor sentiment deteriorated over the past week

Is Surface Oncology (NASDAQ:SURF) Using Too Much Debt?

Surface Oncology Announces the Presentation of New Data from the Ongoing Phase 1 Studies of SRF388 and SRF617

Investor sentiment improved over the past week

Consensus revenue estimates increase to US$28.1m

First quarter 2021 earnings released: US$0.37 loss per share (vs US$0.81 profit in 1Q 2020)

Surface Oncology EPS beats by $0.04, beats on revenue

Surface Oncology, Inc. (NasdaqGM:SURF) acquired worldwide, exclusive, sublicensable license of Vaccinex, Inc. (NasdaqCM:VCNX).

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Analysts lower revenue estimates to US$18.8m

Here's What Surface Oncology, Inc.'s (NASDAQ:SURF) Shareholder Ownership Structure Looks Like

Revenue and earnings beat expectations

Full year 2020 earnings released: EPS US$1.67 (vs US$1.97 loss in FY 2019)

Surface Oncology Collaborates with Merck on Immuno-Oncology Study Evaluating SRF388, Targeting IL-27, in Combination with KEYTRUDA in Patients with Solid Tumors